CREM, Department of Life Sciences, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
Antimicrob Agents Chemother. 2013 Jul;57(7):3037-45. doi: 10.1128/AAC.02621-12. Epub 2013 Apr 15.
In response to β-lactam chemotherapy, Staphylococcus aureus has acquired two resistance determinants: blaZ, coding for β-lactamase, which confers resistance to penicillins only, and mecA, coding for an extra cell wall cross-linking enzyme with reduced affinity for virtually all other β-lactams. The transcriptional control of both resistance determinants is regulated by homologous repressors (BlaI and MecI, respectively) and sensor inducers (BlaR1 and MecR1, respectively). There is a cross-talk between the two regulatory systems, and it has been demonstrated that bla regulators stabilize the mecA acquisition. In a recent study, we have unexpectedly observed that in most MRSA strains, there was no significant change in the resistance phenotype upon the overexpression in trans of a MecI repressor, whereas in those few strains negative for the bla locus, there was a massive decrease of resistance (D. C. Oliveira and H. de Lencastre, PLoS One 6:e23287, 2011). Here, we demonstrate that, contrary to what is currently accepted, the bla regulatory system efficiently disrupts the strong MecI-mediated repression on mecA, enabling the optimal expression of resistance. This effect appears to be due to the formation of MecI::BlaI heterodimers that might bind less efficiently to the mecA promoter and become nonfunctional due to the proteolytic inactivation of the BlaI monomer. In addition, we have also observed that the presence of bla regulators may enhance dramatically the expression of β-lactam resistance in MRSA strains with constitutive mecA expression, compensating for the fitness cost imposed by the large β-lactamase plasmid. These observations point to important unrecognized roles of the bla locus for the expression of the methicillin-resistant S. aureus (MRSA) phenotype.
金黄色葡萄球菌对β-内酰胺化疗产生了两种耐药决定因子:blaZ,编码β-内酰胺酶,仅对青霉素产生耐药性;mecA,编码一种对几乎所有其他β-内酰胺类药物亲和力降低的额外细胞壁交联酶。这两种耐药决定因素的转录控制分别由同源阻遏物(分别为BlaI 和 MecI)和传感器诱导物(分别为BlaR1 和 MecR1)调节。这两个调节系统之间存在交叉对话,并且已经证明bla 调节剂稳定了 mecA 的获得。在最近的一项研究中,我们出人意料地观察到,在大多数 MRSA 菌株中,当 mecI 阻遏物在转位中过表达时,其耐药表型没有明显变化,而在那些 bla 基因座阴性的少数菌株中,耐药性则大大降低(D. C. Oliveira 和 H. de Lencastre,PLoS One 6:e23287, 2011)。在这里,我们证明,与目前公认的情况相反,bla 调节系统能够有效地破坏 mecA 上由 MecI 介导的强烈抑制,从而使耐药性得到最佳表达。这种效应似乎是由于形成了 MecI::BlaI 异二聚体,其与 mecA 启动子的结合效率可能较低,并且由于 BlaI 单体的蛋白水解失活而变得无功能。此外,我们还观察到,bla 调节剂的存在可能会极大地增强具有组成型 mecA 表达的 MRSA 菌株中β-内酰胺耐药性的表达,从而弥补大β-内酰胺酶质粒带来的适应性代价。这些观察结果指出了 bla 基因座对耐甲氧西林金黄色葡萄球菌(MRSA)表型表达的重要而未被认识的作用。